Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-02-09

FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approves a supplemental application for buspirone hydrochloride from Mylan Pharmaceuticals Inc. This is an ANDA-related approval for a generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buspirone hydrochloride (buspirone hydrochloride)

Snippet

SUPPL AP for BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE)